ASTHMA
Conditions
Keywords
Asthma, phenotype, small, airway, proximal, dysfunction
Brief summary
The aim of the study is to describe asthma phenotype with small airways dysfunction, in a multiparametric manner, with clinical, biological, morphological and genetic elements compared with asthma with proximal airways obstruction. The objective of this study is also to complete the clinical, immunobiological and morphological analysis of asthma with small airways dysfunction.
Interventions
GENETICasthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.
symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
GENETICasthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.
symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Inclusion Criteria: * man or woman * age ≥ 18 years * asthma * inform consent signed * affiliated to health insurance Specific inclusion criteria : asthma with proximal airways obstruction GROUP * Maximal Voluntary Ventilation (MMV)\<80% * MMV / Forced Vital Capacity (FVC)≤70% * Carbon Monoxide Transfer Coefficient (KcO)\>80% Specific inclusion criteria : asthma with small airways dysfunction GROUP * Maximal Voluntary Ventilation (MMV)≥80% * MMV / Vital Capacity(VC)\>70% * Carbon Monoxide Transfer Coefficient (KcO)\>80% General
Exclusion criteria
* pregnant woman or breastfeeding * patient participating to other biomedical research * patient who have participated to other biomedical research within the past 3 months * patient refusing to sign the inform consent Specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| mRNA expression levels. | maximum 4 weeks after the inclusion visit. | mRNA expression levels will be measured by microarray analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| biological asthma profile : allergologic patch test | maximum 4 weeks after the inclusion visit. | allergologic patch test |
| biological asthma profile : IgE analysis | maximum 4 weeks after the inclusion visit. | IgE analysis |
| clinical asthma profile : comorbidities | maximum 4 weeks after the inclusion visit. | comorbidities |
| clinical asthma profile : increased factors related to asthma. | maximum 4 weeks after the inclusion visit. | increased factors related to asthma. |
| biological asthma profile :blood eosinophils | maximum 4 weeks after the inclusion visit. | blood eosinophils |
| biological asthma profile : blood periostin | maximum 4 weeks after the inclusion visit. | blood periostin |
| clinical asthma profile : medical history | maximum 4 weeks after the inclusion visit. | medical history |
| clinical asthma profile : date of start | maximum 4 weeks after the inclusion visit. | date of start |
| clinical asthma profile : date of aggravation | maximum 4 weeks after the inclusion visit. | date of aggravation |
| morphological asthma profile : Chest X Ray (tomodensitometric test). | maximum 4 weeks after the inclusion visit. | Chest X Ray (tomodensitometric test). |
| clinical asthma profile : symptoms | maximum 4 weeks after the inclusion visit. | symptoms |
Countries
France
Outcome results
None listed